DuPont raises full-year profit forecasts on strong healthcare, aerospace demand

Pfizer has increased its 2026 forecast following strong demand for the blood thinner Eliquis. Similarly, DuPont has raised its full-year profit forecasts, citing robust demand within the healthcare and aerospace sectors. Both companies are adjusting their financial outlooks upward based on the high market demand for their specific products and services. These updates reflect positive growth trajectories for Pfizer and DuPont as they capitalize on strong performance across their respective healthcare and aerospace portfolios.